- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01969838
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor).
Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 216 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those participants planning to continue treatment with MMB following the end of the study, the Early Study Drug Discontinuation (ESDD), 30-day, 12-Week, and survival follow-up visits are not required.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia
-
Parkville, New South Wales, Australia
-
Saint Leonards, New South Wales, Australia
-
-
Queensland
-
Brisbane, Queensland, Australia
-
Herston, Queensland, Australia
-
-
South Australia
-
Adelaide, South Australia, Australia
-
Bedford Park, South Australia, Australia
-
-
Victoria
-
Frankston, Victoria, Australia
-
Melbourne, Victoria, Australia
-
-
Western Australia
-
Perth, Western Australia, Australia
-
-
-
-
Vienna
-
Wien, Vienna, Austria
-
-
-
-
-
Antwerp, Belgium
-
Leuven, Belgium
-
Liege, Belgium
-
-
Hainaut
-
Charleroi, Hainaut, Belgium
-
-
-
-
-
Pleven, Bulgaria
-
Plovdiv, Bulgaria
-
Ruse, Bulgaria
-
Sofia, Bulgaria
-
Varna, Bulgaria
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Ontario
-
Hamilton, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
-
-
-
Brno, Czechia
-
Ostrava, Czechia
-
-
Vychodocesky KRAJ
-
Hradec Kralove, Vychodocesky KRAJ, Czechia
-
-
-
-
-
Aalborg, Denmark
-
Herlev, Denmark
-
-
-
-
-
Le Kremlin Bicetre Cedex, France
-
Lens, France
-
Lille Cedex, France
-
Marseille Cedex 9, France
-
Nantes cedex 1, France
-
Paris, France
-
Pessac Cedex, France
-
Villejuif Cedex, France
-
-
Midi-pyrenees
-
Toulouse cedex 9, Midi-pyrenees, France
-
-
Rhone-alpes
-
Pierre Bénite Cedex, Rhone-alpes, France
-
-
-
-
-
Dresden, Germany
-
Dusseldorf, Germany
-
Freiburg, Germany
-
Hamburg, Germany
-
Mainz, Germany
-
Mannheim, Germany
-
-
Bayern
-
München, Bayern, Germany
-
-
Sachsen
-
Leipzig, Sachsen, Germany
-
-
-
-
-
Budapest, Hungary
-
Debrecen, Hungary
-
Kaposvár, Hungary
-
-
-
-
-
Afula, Israel
-
Ashkelon, Israel
-
Haifa, Israel
-
Jerusalem, Israel
-
Tel Aviv, Israel
-
-
-
-
-
Bunkyo-ku, Tokyo, Japan
-
Fukushima City, Japan
-
Kumamoto City, Japan
-
Matsuyama, Japan
-
Okayama, Japan
-
-
Gifu
-
Ogaki City, Gifu, Japan
-
-
Hokkaido
-
Kitaku Sapporo, Hokkaido, Japan
-
-
Osaka
-
Osaka Sayama, Osaka, Japan
-
Osaka-City, Osaka, Japan
-
-
-
-
-
Seoul, Korea, Republic of
-
-
-
-
-
Maastricht, Netherlands
-
Nijmegen, Netherlands
-
Rotterdam, Netherlands
-
Utrecht, Netherlands
-
-
-
-
-
Bialystok, Poland
-
Brzozow, Poland
-
Chorzow, Poland
-
-
Lodzkie
-
Lodz, Lodzkie, Poland
-
-
Lubelskie
-
Lublin, Lubelskie, Poland
-
-
Malopolskie
-
Kraków, Malopolskie, Poland
-
-
Mazowiekie
-
Warszawa, Mazowiekie, Poland
-
-
Pomorskie
-
Gdansk, Pomorskie, Poland
-
-
Wielkopolskie
-
Poznan, Wielkopolskie, Poland
-
-
-
-
-
Arad, Romania
-
Brasov, Romania
-
Bucuresti, Romania
-
Cluj-Napoca, Romania
-
Iasi, Romania
-
-
-
-
-
Singapore, Singapore
-
-
-
-
-
Badalona, Spain
-
Barcelona, Spain
-
Valencia, Spain
-
Zaragoza, Spain
-
-
Madrid
-
Majadahonda, Madrid, Spain
-
-
Navarra
-
Pamplona, Navarra, Spain
-
-
-
-
-
Stockholm, Sweden
-
Uddevalla, Sweden
-
Örebro, Sweden
-
-
Skane
-
Lund, Skane, Sweden
-
-
-
-
-
Kaohsiung, Taiwan
-
-
-
-
-
Northern Ireland, United Kingdom
-
Nottingham, United Kingdom
-
-
England
-
Leicester, England, United Kingdom
-
London, England, United Kingdom
-
Manchester, England, United Kingdom
-
Newcastle Upon Tyne, England, United Kingdom
-
Oxford, England, United Kingdom
-
-
Wales
-
Cardiff, Wales, United Kingdom
-
-
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
California
-
Escondido, California, United States
-
Stanford, California, United States
-
-
Florida
-
Jacksonville, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
North Carolina
-
Durham, North Carolina, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Palpable splenomegaly at least 5 cm below the left costal margin
- Confirmed diagnosis of PMF or post-PV/ET MF
- Requires myelofibrosis therapy, in the opinion of the investigator
- Classified as high risk OR intermediate-2 risk as defined by the International Prognostic Scoring System (IPSS) for PMF, or intermediate-1 risk (IPSS) associated with symptomatic splenomegaly, hepatomegaly, anemia (hemoglobin < 10.0 g/dL), and/or unresponsive to available therapy
Acceptable laboratory assessment obtained within 14 days prior to the first dose of study drug:
- Absolute neutrophil count (ANC) ≥ 0.75 x 10^9/L in the absence of growth factor in the prior 7 days
- Platelet Count ≥ 50 x 10^9/L (≥ 100 x 10^9/L if aspartate aminotransferase [AST] or alanine aminotransferase [ALT] is ≥ 2 x the upper limit of the normal range [ULN]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in the prior 7 days
- Peripheral blood blast count < 10%
- AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
- Calculated creatinine clearance (CrCL) of ≥ 45 mL/min
- Direct bilirubin ≤ 2.0 x ULN
- Life expectancy of > 24 weeks
- Males and females of childbearing potential must agree to use protocol-specified method(s) of contraception
- Females who are nursing must agree to discontinue nursing before the first dose of study drug
- Able to understand and willing to sign the informed consent form
Key Exclusion Criteria:
- Prior splenectomy
- Splenic irradiation within 3 months prior to the first dose of study drug
- Eligible for allogeneic bone marrow or stem cell transplantation
- Uncontrolled inter-current illness, per protocol.
- Known positive status for human immunodeficiency virus (HIV)
- Chronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
- Prior use of a JAK1 or JAK2 inhibitor
- Use of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy, or investigational therapy within 4 weeks of the first dose of study drug
- Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
- Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Momelotinib
Participants will receive momelotinib plus placebo to match ruxolitinib.
|
Momelotinib tablet administered orally once daily
Other Names:
Placebo to match ruxolitinib tablets administered orally twice daily
|
Active Comparator: Ruxolitinib
Participants will receive ruxolitinib plus placebo to match momelotinib.
|
Ruxolitinib tablets administered orally twice daily
Placebo to match momelotinib tablets administered orally once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Splenic Response Rate at Week 24
Time Frame: Week 24
|
Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Symptom Score (TSS) Response Rate at Week 24
Time Frame: Week 24
|
Total symptom score (TSS) is defined as the percentage of participants who achieved a ≥50% reduction in TSS at Week 24 versus baseline as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary. Response rate was calculated using the average of the daily TSS from a consecutive 28-day period prior to Week 24, which had ≥20 daily TSS available. The modified MPN-SAF patient-reported outcome instrument consisted of 8 items assessing worst daily incidence of tiredness, filling up quickly, abdominal discomfort, night sweats, itching, bone pain, pain under ribs on left side, and inactivity. Scoring of the Total Symptom Score (TSS), in this study was based on 7 of these items, (range of 0-70,), excluding inactivity. These items assess the impact experienced by the participant in the 24 hours prior to completing the questionnaire. All items are measured using a 0 to 10 Numeric Rating Scale, with 0 corresponding to "Absent" and 10 being the worse |
Week 24
|
Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)
Time Frame: Baseline to Week 24
|
Rate of RBC transfusion was defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the double-blind phase.
|
Baseline to Week 24
|
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)
Time Frame: Week 24
|
RBC transfusion independence is the percentage of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.
|
Week 24
|
RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)).
Time Frame: Week 24
|
RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as having had at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in 8 weeks prior to Week 24 (excluding cases associated with clinically overt bleeding).
Participants with the last double-blind phase participation date prior to Day 162 (ie.
missing at Week 24) were considered transfusion dependent at Week 24.
|
Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gilead Study Director, Gilead Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Primary Myelofibrosis
- Thrombocytosis
- Thrombocythemia, Essential
- Polycythemia Vera
- Polycythemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Other Study ID Numbers
- GS-US-352-0101
- 2013-002707-33 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Myelofibrosis
-
Assaf-Harofeh Medical CenterUnknownMyelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ETIsrael
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
AbbVieRecruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
-
AbbVieTerminatedMyelofibrosis (MF)United States, Korea, Republic of, South Africa
-
Centre Hospitalier Annecy GenevoisCompleted
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingModerate and High Risk MyelofibrosisChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Clinical Trials on Momelotinib
-
Sierra Oncology LLC - a GSK companyTerminatedMetastatic Pancreatic Ductal AdenocarcinomaUnited States
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisKorea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, Canada, Australia
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocythemia MyelofibrosisUnited States, Canada
-
M.D. Anderson Cancer CenterGlaxoSmithKlineNot yet recruiting
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, Canada, Australia
-
GlaxoSmithKlineNo longer availablePrimary Myelofibrosis | Myelofibrosis
-
Sierra Oncology, Inc.TerminatedPolycythemia Vera | Essential ThrombocythemiaUnited States, France, Germany, Canada, Australia
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, France, Canada, Germany, Australia
-
Sierra Oncology, Inc.TerminatedRelapsed Metastatic KRAS-Mutated Non-Small Cell Lung CancerUnited States